New hope for lymphoma: immune booster plus chemotherapy trial launches
NCT ID NCT07588698
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding epcoritamab, an immune-boosting drug, to standard R-CHOP chemotherapy can safely treat newly diagnosed aggressive B-cell lymphoma. About 20 adults with certain lymphoma types will receive the combination. The main goal is to check for a side effect called cytokine release syndrome, while also tracking overall safety and how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Epcoritamab (a drug that helps the immune system attack cancer cells) combined with R-CHOP chemotherapy
- What this could lead to
- If successful, this combination could improve treatment outcomes for people with aggressive B-cell lymphoma, potentially leading to better disease control and fewer relapses.
- What could go wrong
- This is an early Phase 2 trial with only 20 participants, so results may not apply to everyone. The combination may cause serious side effects like cytokine release syndrome (CRS), and it's not yet known if it works better than standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Contact Email: •••••@•••••
-
Zuckerberg San Francisco General
San Francisco, California, 94110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a targeted drug boost standard chemo for an aggressive lymphoma?